This approach helps your digestive system adapt and reduces the severity of side effects
It leads to high blood sugar levels that can increase the risk of heart or kidney disease and nerve or vision damage
[17] Gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), has been observed with incretin-based therapies
US Food and Drug Administration (FDA) Approvals of GLP-1 and GLP1/GIP RAs 11,22-34 However, these labels are being expanded to include additional indications for patients with a spectrum of other cardiometabolic conditions, such as obesity, cardiovascular disease, chronic kidney disease, and obstructive sleep apnea
That search led her to the Noom Microdose GLP-1 Rx Program
Another option is new pills to treat obesity, which will be cheaper than their injectable counterparts